Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin acute MI indication public education effort by FDA urged in Bayer comments.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN ACUTE MI INDICATION PUBLIC EDUCATION EFFORTS BY FDA RECOMMENDED by Bayer Consumer Care in Sept. 11 comments on the agency's recently proposed professional labeling claim for aspirin. Published June 13, FDA's proposal would amend the tentative final monograph for OTC internal analgesic, antipyretic and antirheumatic drugs to include professional labeling of aspirin products for reduced "risk of vascular mortality in people with suspected acute myocardial infarction (MI)" ("The Tan Sheet" June 17, p. 3).

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts